Tweet
You know, there are some guys who have an incredible intellect, and some other guys have a top 1% bench press, and there are some other guys who can pick winning stocks so easily it almost seems incredible. Then there is $$$MR. MARKET$$$, who does all of the above.
Today I sold MASI at $108.75. That’s a 16% gain over my purchase price of 93.69.
That makes 81 consecutive profitable trades of 15% or better. Can you do that? You? YOU? YOU??! You just have to love $$$MR. MARKET$$$. If you don’t, then you must hate money.
I am HUGE! Bring me your finest meats and cheeses for I am the finest stock picker living on this planet . Just how huge is $$$MR. MARKET$$$?
I’m ready to make some more stock picks. Does anyone want to see a new one?
$$$MR. MARKET$$$
================================================== ======================
03-18-2017, 04:14 PM
MASI ==> The Nor'Easter Winner
When $$$MR. MARKET$$$ was a junior in high school, he had the privilege of being one of the starting wrestlers on the championship Roxbury Latin School wrestling team. Now this didn’t go without its sacrifices. $$$MR. MARKET$$$ had to cut a ton of weight to secure his spot at 152 lbs. Wrestling at 160 was Bendo, one of the premier wrestlers in New England. $$$MR. MARKET$$$’s football buddy and practice wrestling partner was Michael P at 167 and weighing in at 177 was a rookie by the name of Paul Massey. Shortly after the season started, Michael P. was brought down by an unfortunate shoulder injury during an unnecessary wrestle-off. This made $$$MR. MARKET$$$ very sad, because the thought of wrestling Bendo every day in practice was not very appealing. Bendo could bend $$$MR. MARKET$$$ into a pretzel any time that he wanted to, and he seemed to enjoy that quite a bit. So, despite the difference in size, $$$MR. MARKET$$$ preferred practicing with Paul Massey as they both worked hard and were successful as the team went 11-1 on the year and secured the league championship.
Massey went on from his rookie season to become a champion wrestler in his own right. What’s the point of this story? Well, Paul Massey is now running for Mayor of New York City. He was a great wrestler, and I am sure he’d make a great mayor too.
With that in mind, yesterday I bought stock in Masimo Corporation (MASI) at 93.69. I will sell it in 4 -6 weeks at 107.91.
Here’s why I like MASI:
First of all, you have to love the chart. It is an exquisite thing of beauty:
This stock just wants to go up, up and up. It is the purest momentum stock I have seen in a long time. The moving average line is so steady, like the hands of a famous plastic surgeon who lives in Vero Beach. Masimo Corp (MASI) is a recognized expert in the monitoring technology sector, known for manufacturing innovative patient monitoring technologies and pushing the boundaries of modern health care. You know when you’re in the hospital and all of those expensing machines are going beep beep beep beep…yup that’s the sound of money!
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies
worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
As a society, we are relying on technology to provide us with the necessary productivity and efficiency that is needed in the health care space. If you combine this with the increased demand for healthcare (population is growing and we’re living longer – that means more dollars every year being spent on healthcare) – you have to believe that companies like MASI, who are on the forefront of technology, will benefit greatly from these macro trends. You know how they check the oxygen in your blood with that fingertip thingy (which is in like every hospital room, by the way) without even drawing your blood? Amazing.
MASI stock is up 130% in the last 12 months. The stock is up over 400% in the last 3 years and it just doesn’t stop. This is a 4.7 billion dollar company with a 43% profit margin. We’re not fooling around here. The reason why this stock is on such a steady climb is that it is an earnings machine and it seems like almost every month they are announcing a new product that will be a value contributor to health care technology. For example:
Masimo (MASI) announced recently the publication of a recent study conducted on adult patients undergoing liver transplantation (LT), in which researchers assessed the accuracy and trending ability of noninvasive Masimo SpHb® (total hemoglobin) measurement, as compared to conventional laboratory hemoglobin (HbL) measurements. The researchers found that SpHb had “clinically acceptable accuracy of hemoglobin measurement [compared] with a standard laboratory device when used during LT” and that “[t]his technology can be useful as a trend monitor during all surgical phases of LT and can supplement HbL to optimize transfusion decisions or to detect occult bleeding.” This is a HUGE clinical advantage and it is almost certain that MASI will be able to leverage this technology into other important monitoring devices.
The stock is primarily suitable for growth investors. However, it is also suitable for those looking for value and to a lesser degree momentum. Post-election, the healthcare industry has been grappling with multiple issues, with the Obamacare saga dominating headlines. Meanwhile, Republicans have proposed a new draft legislation – The American Healthcare Act (AHA) – to replace Obamacare, also known as the Affordable Care Act (ACA).
One of the greatest boons of abolishing Obamacare will be the eradication of medical device taxes., A repeal of this tax shuld bolster hiiring and investment among the U.S.-based medical device manufacturers, including MASI.
One thing to remember is that MASI’s international sales jumped nearly 12%, with Latin America and Asia showcasing solid growth, last year. In the just-reported fourth quarter, the company witnessed growth of 20% to 40% in the international markets on a year-over-year basis. So not matter what happens in the US of A. with the ACA MASI still has customers all of the world banking on its technology to treat aging patients.
The company's rich product portfolio is marked by a few stand-out offerings: Masimo SET pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and the new Masimo noninvasive and continuous total hemoglobin monitoring technology. Licensing and OEM agreements with leading patient monitoring manufacturers like Atom, General Electric (GE) Medical, Medtronic (MDT) , Philips, and Zoll will help Masimo secure more revenue streams. For fiscal year 2016, total revenue grew 11.5% to $694.6 million and product revenue increased 11% to $664 million.
Masimo is providing 2017 financial guidance. Masimo expects total fiscal 2017 revenues to be approximately $752.0 million, including $721.0 million in product and other revenues and $31.0 million in royalty revenues. Masimo expects fiscal 2017 earnings per diluted share to be approximately $2.30 per diluted share. ANAL-ysts project 6.4% earnings per share growth in 2017, and a five-year run-rate of 15%. This long-term earnings growth outlook is much faster than the 8.9% S&P 500 benchmark, as well as the company's larger rivals like Medtronic and Boston Scientific (BSX) Their balance sheet is flush with cash and nearly debt free. EPS growth in past five years was 40.10% while EPS growth in next five years is projected to arrive at 15.00%. Sales growth past 5 years was measured at 9.60%.
Fourth quarter 2016 product revenues rose 10.0% to $175.7 million, compared to $159.8 million for the fourth quarter of fiscal year 2015, and total revenue, including royalties, rose 9.5% to $183.2 million, up from $167.3 million for the fourth quarter of fiscal year 2015.
The Company’s worldwide direct product revenue in the fourth quarter of 2016 rose by 10.8% compared to the same period in 2015 and represented 87.0% of product revenue. OEM sales, which accounted for 13.0% of product revenue, rose by 4.8% to $22.9 million in the fourth quarter of 2016 compared to the same period in 2015.
Norges Bank purchased a new position in Masimo Corporation during the fourth quarter worth approximately $26,532,000. Thrivent Financial for Lutherans boosted its position in Masimo Corporation by 6.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 23,760 shares of the company’s stock worth $1,601,000 after buying an additional 1,390 shares during the last quarter. Narus Financial Partners LLC purchased a new position in Masimo Corporation during the fourth quarter worth approximately $428,000. Summit Global Investments purchased a new position in Masimo Corporation during the fourth quarter worth approximately $593,000. Finally, RTW Investments LP boosted its position in Masimo Corporation by 212.4% in the fourth quarter. RTW Investments LP now owns 80,900 shares of the company’s stock worth $5,453,000 after buying an additional 55,000 shares during the last quarter. Institutional investors own 82.14% of the company’s stock. Hey, I don’t follow these guys. I don’t follow anyone. I make my own decisions, but I thought it was interesting to reflect on the institutional money that also is riding the MASI train. Choo Choo!
What’s unique about MASI? You can start with the Founder, Chairman and CEO who started this company in his garage nearly 30 years ago.
Joe Kiani is an inventor of world-changing noninvasive patient monitoring devices, a trusted voice for patient safety and care, and a convention-breaking maverick. As the founder, Chairman, and CEO of Masimo, a global medical technology innovator, Mr. Kiani has been a beacon for patient safety and innovation in healthcare for more than 25 years. Convinced that the use of adaptive signal processing could solve the problems of motion artifact and noise that plagued pulse oximetryhe founded Masimo in 1989 to improve patient outcome and reduce the cost of care by taking noninvasive monitoring to new sites and applications.
Under his leadership, Masimo has grown from a “garage start up” into a successful publicly traded company employing more than 3,500 people worldwide and providing its technology and clinical-leading Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry technology directly and through leading OEM patient monitoring manufacturers.
You can go to the video tape and look at performance measures. Return on assets is 13%, Return on equity is a ridiculous 72%.
MASI shipped 48,600 oximeters in Q4, a new quarterly record, producing total shipments for 2016 of 186,000 oximeters. Their total global installed base is over 1.5 million oximeter. That’s a lot of beeping…the sound of money.
As a reminder, fiscal 2017 represents the final year of their 10-year post-IPO plan and the company is confident that the momentum they have built will allow them to finish this 10-year plan strongly. They already have an investor day planned to unveil their next 10 year plan. This is clearly a company with a vision of success and with this success will come an increase in stock price!
Mr. Kiani recently said:
“We are happy to report another strong quarter, with topline revenues in excess of our expectations and operating income at a new record level. As seen throughout 2016, we again experienced strong US product revenue growth due to a combination of higher utilization, new customers, and incremental revenues from our new products, such as Nomoline capnography, O3 regional oximetry, SedLine brain function monitoring, and Root patient monitoring and connectivity hub.
We attribute our strong quarterly and full-year performance to our technologically advanced product portfolio and its proven value to improve patient outcomes and reduce costs, as well as the exceptional abilities of the Masimo team.
“We are happy to report that we were able to finish the year on a very strong note as demand for our products throughout the world continues to increase with an especially strong fourth quarter in the U.S. Healthy product revenue growth, coupled with continued product margin expansion and controlled operating expenses, has allowed Masimo to achieve the highest quarterly operating income in our history. We are also very happy to report that our estimate of total worldwide installed base has for the first time ever exceeded 1.5 million SET® Pulse Oximeters and rainbow SET™ Pulse CO-Oximeters.”
I didn't dive deep on the valuation of this company because it keeps growing like an amoeba. All of the macro elements are in place for demand for its products to grow while they keep making new products to serve their existing market. I am confident this stock will reach my target. With the money I make on MASI, I will make a donation to the Paul Massey for NYC mayor campaign and with what I have left over, I will eat a HUGE mutton chop at Keens Steakhouse in NYC after Paul wins the election.
I am HUGE!!
$$$MR. MARKET$$$
Last edited by mrmarket; 05-20-2017 at 09:55 AM.
=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$
Today I sold MASI at $108.75. That’s a 16% gain over my purchase price of 93.69.
That makes 81 consecutive profitable trades of 15% or better. Can you do that? You? YOU? YOU??! You just have to love $$$MR. MARKET$$$. If you don’t, then you must hate money.
I am HUGE! Bring me your finest meats and cheeses for I am the finest stock picker living on this planet . Just how huge is $$$MR. MARKET$$$?
- $$$MR. MARKET$$$ once ate a Rubics cube and it came out the other end completely solved.
- $$$MR. MARKET$$$ stared at a solar eclipse too long and the sun ended up blind.
- One time $$$MR. MARKET$$$ was pulled over by a policeman, and $$$MR. MARKET$$$ let him go with just a warning.
I’m ready to make some more stock picks. Does anyone want to see a new one?
$$$MR. MARKET$$$
================================================== ======================
03-18-2017, 04:14 PM
MASI ==> The Nor'Easter Winner
When $$$MR. MARKET$$$ was a junior in high school, he had the privilege of being one of the starting wrestlers on the championship Roxbury Latin School wrestling team. Now this didn’t go without its sacrifices. $$$MR. MARKET$$$ had to cut a ton of weight to secure his spot at 152 lbs. Wrestling at 160 was Bendo, one of the premier wrestlers in New England. $$$MR. MARKET$$$’s football buddy and practice wrestling partner was Michael P at 167 and weighing in at 177 was a rookie by the name of Paul Massey. Shortly after the season started, Michael P. was brought down by an unfortunate shoulder injury during an unnecessary wrestle-off. This made $$$MR. MARKET$$$ very sad, because the thought of wrestling Bendo every day in practice was not very appealing. Bendo could bend $$$MR. MARKET$$$ into a pretzel any time that he wanted to, and he seemed to enjoy that quite a bit. So, despite the difference in size, $$$MR. MARKET$$$ preferred practicing with Paul Massey as they both worked hard and were successful as the team went 11-1 on the year and secured the league championship.
Massey went on from his rookie season to become a champion wrestler in his own right. What’s the point of this story? Well, Paul Massey is now running for Mayor of New York City. He was a great wrestler, and I am sure he’d make a great mayor too.
With that in mind, yesterday I bought stock in Masimo Corporation (MASI) at 93.69. I will sell it in 4 -6 weeks at 107.91.
Here’s why I like MASI:
First of all, you have to love the chart. It is an exquisite thing of beauty:
This stock just wants to go up, up and up. It is the purest momentum stock I have seen in a long time. The moving average line is so steady, like the hands of a famous plastic surgeon who lives in Vero Beach. Masimo Corp (MASI) is a recognized expert in the monitoring technology sector, known for manufacturing innovative patient monitoring technologies and pushing the boundaries of modern health care. You know when you’re in the hospital and all of those expensing machines are going beep beep beep beep…yup that’s the sound of money!
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies
worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
As a society, we are relying on technology to provide us with the necessary productivity and efficiency that is needed in the health care space. If you combine this with the increased demand for healthcare (population is growing and we’re living longer – that means more dollars every year being spent on healthcare) – you have to believe that companies like MASI, who are on the forefront of technology, will benefit greatly from these macro trends. You know how they check the oxygen in your blood with that fingertip thingy (which is in like every hospital room, by the way) without even drawing your blood? Amazing.
MASI stock is up 130% in the last 12 months. The stock is up over 400% in the last 3 years and it just doesn’t stop. This is a 4.7 billion dollar company with a 43% profit margin. We’re not fooling around here. The reason why this stock is on such a steady climb is that it is an earnings machine and it seems like almost every month they are announcing a new product that will be a value contributor to health care technology. For example:
Masimo (MASI) announced recently the publication of a recent study conducted on adult patients undergoing liver transplantation (LT), in which researchers assessed the accuracy and trending ability of noninvasive Masimo SpHb® (total hemoglobin) measurement, as compared to conventional laboratory hemoglobin (HbL) measurements. The researchers found that SpHb had “clinically acceptable accuracy of hemoglobin measurement [compared] with a standard laboratory device when used during LT” and that “[t]his technology can be useful as a trend monitor during all surgical phases of LT and can supplement HbL to optimize transfusion decisions or to detect occult bleeding.” This is a HUGE clinical advantage and it is almost certain that MASI will be able to leverage this technology into other important monitoring devices.
The stock is primarily suitable for growth investors. However, it is also suitable for those looking for value and to a lesser degree momentum. Post-election, the healthcare industry has been grappling with multiple issues, with the Obamacare saga dominating headlines. Meanwhile, Republicans have proposed a new draft legislation – The American Healthcare Act (AHA) – to replace Obamacare, also known as the Affordable Care Act (ACA).
One of the greatest boons of abolishing Obamacare will be the eradication of medical device taxes., A repeal of this tax shuld bolster hiiring and investment among the U.S.-based medical device manufacturers, including MASI.
One thing to remember is that MASI’s international sales jumped nearly 12%, with Latin America and Asia showcasing solid growth, last year. In the just-reported fourth quarter, the company witnessed growth of 20% to 40% in the international markets on a year-over-year basis. So not matter what happens in the US of A. with the ACA MASI still has customers all of the world banking on its technology to treat aging patients.
The company's rich product portfolio is marked by a few stand-out offerings: Masimo SET pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and the new Masimo noninvasive and continuous total hemoglobin monitoring technology. Licensing and OEM agreements with leading patient monitoring manufacturers like Atom, General Electric (GE) Medical, Medtronic (MDT) , Philips, and Zoll will help Masimo secure more revenue streams. For fiscal year 2016, total revenue grew 11.5% to $694.6 million and product revenue increased 11% to $664 million.
Masimo is providing 2017 financial guidance. Masimo expects total fiscal 2017 revenues to be approximately $752.0 million, including $721.0 million in product and other revenues and $31.0 million in royalty revenues. Masimo expects fiscal 2017 earnings per diluted share to be approximately $2.30 per diluted share. ANAL-ysts project 6.4% earnings per share growth in 2017, and a five-year run-rate of 15%. This long-term earnings growth outlook is much faster than the 8.9% S&P 500 benchmark, as well as the company's larger rivals like Medtronic and Boston Scientific (BSX) Their balance sheet is flush with cash and nearly debt free. EPS growth in past five years was 40.10% while EPS growth in next five years is projected to arrive at 15.00%. Sales growth past 5 years was measured at 9.60%.
Fourth quarter 2016 product revenues rose 10.0% to $175.7 million, compared to $159.8 million for the fourth quarter of fiscal year 2015, and total revenue, including royalties, rose 9.5% to $183.2 million, up from $167.3 million for the fourth quarter of fiscal year 2015.
The Company’s worldwide direct product revenue in the fourth quarter of 2016 rose by 10.8% compared to the same period in 2015 and represented 87.0% of product revenue. OEM sales, which accounted for 13.0% of product revenue, rose by 4.8% to $22.9 million in the fourth quarter of 2016 compared to the same period in 2015.
Norges Bank purchased a new position in Masimo Corporation during the fourth quarter worth approximately $26,532,000. Thrivent Financial for Lutherans boosted its position in Masimo Corporation by 6.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 23,760 shares of the company’s stock worth $1,601,000 after buying an additional 1,390 shares during the last quarter. Narus Financial Partners LLC purchased a new position in Masimo Corporation during the fourth quarter worth approximately $428,000. Summit Global Investments purchased a new position in Masimo Corporation during the fourth quarter worth approximately $593,000. Finally, RTW Investments LP boosted its position in Masimo Corporation by 212.4% in the fourth quarter. RTW Investments LP now owns 80,900 shares of the company’s stock worth $5,453,000 after buying an additional 55,000 shares during the last quarter. Institutional investors own 82.14% of the company’s stock. Hey, I don’t follow these guys. I don’t follow anyone. I make my own decisions, but I thought it was interesting to reflect on the institutional money that also is riding the MASI train. Choo Choo!
What’s unique about MASI? You can start with the Founder, Chairman and CEO who started this company in his garage nearly 30 years ago.
Joe Kiani is an inventor of world-changing noninvasive patient monitoring devices, a trusted voice for patient safety and care, and a convention-breaking maverick. As the founder, Chairman, and CEO of Masimo, a global medical technology innovator, Mr. Kiani has been a beacon for patient safety and innovation in healthcare for more than 25 years. Convinced that the use of adaptive signal processing could solve the problems of motion artifact and noise that plagued pulse oximetryhe founded Masimo in 1989 to improve patient outcome and reduce the cost of care by taking noninvasive monitoring to new sites and applications.
Under his leadership, Masimo has grown from a “garage start up” into a successful publicly traded company employing more than 3,500 people worldwide and providing its technology and clinical-leading Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry technology directly and through leading OEM patient monitoring manufacturers.
You can go to the video tape and look at performance measures. Return on assets is 13%, Return on equity is a ridiculous 72%.
MASI shipped 48,600 oximeters in Q4, a new quarterly record, producing total shipments for 2016 of 186,000 oximeters. Their total global installed base is over 1.5 million oximeter. That’s a lot of beeping…the sound of money.
As a reminder, fiscal 2017 represents the final year of their 10-year post-IPO plan and the company is confident that the momentum they have built will allow them to finish this 10-year plan strongly. They already have an investor day planned to unveil their next 10 year plan. This is clearly a company with a vision of success and with this success will come an increase in stock price!
Mr. Kiani recently said:
“We are happy to report another strong quarter, with topline revenues in excess of our expectations and operating income at a new record level. As seen throughout 2016, we again experienced strong US product revenue growth due to a combination of higher utilization, new customers, and incremental revenues from our new products, such as Nomoline capnography, O3 regional oximetry, SedLine brain function monitoring, and Root patient monitoring and connectivity hub.
We attribute our strong quarterly and full-year performance to our technologically advanced product portfolio and its proven value to improve patient outcomes and reduce costs, as well as the exceptional abilities of the Masimo team.
“We are happy to report that we were able to finish the year on a very strong note as demand for our products throughout the world continues to increase with an especially strong fourth quarter in the U.S. Healthy product revenue growth, coupled with continued product margin expansion and controlled operating expenses, has allowed Masimo to achieve the highest quarterly operating income in our history. We are also very happy to report that our estimate of total worldwide installed base has for the first time ever exceeded 1.5 million SET® Pulse Oximeters and rainbow SET™ Pulse CO-Oximeters.”
I didn't dive deep on the valuation of this company because it keeps growing like an amoeba. All of the macro elements are in place for demand for its products to grow while they keep making new products to serve their existing market. I am confident this stock will reach my target. With the money I make on MASI, I will make a donation to the Paul Massey for NYC mayor campaign and with what I have left over, I will eat a HUGE mutton chop at Keens Steakhouse in NYC after Paul wins the election.
I am HUGE!!
$$$MR. MARKET$$$
Last edited by mrmarket; 05-20-2017 at 09:55 AM.
=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$
Comment